||Srdan Verstovsek, MD, PhD
Professor, Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
|Dr. Srdan Verstovsek is a medical oncologist and Professor in the Department of
Leukemia at the University of Texas MD Anderson Cancer Center. He received his
medical degree in 1992 from the School of Medicine, University of Zagreb, Croatia.
While receiving medical education, he spent his summer semesters working at the
Roswell Park Cancer Institute in Buffalo, New York and after graduation from
medical school he continued his research activities there and was awarded his doctorate. Dr. Verstovsek
went on to complete an Internal Medicine Residency at the State University of New York in Buffalo
followed by the Oncology-Hematology Fellowship at MD Anderson. He has been a part of the Leukemia
Department at M. D. Anderson since 2001. Dr. Verstovsek has maintained an active interest in leukemia
during most of his research and clinical training with emphasis on experimental therapeutics and
translational research. His main clinical interest is myeloproliferative disorders.
Medical Degree: School of Medicine, University of Zagreb, Zagreb, Croatia
Doctorate: Medical Science, University of Zagreb, Zagreb, Croatia
Residency: Internal Medicine, Roswell Cancer Institute, University of Buffalo, Buffalo, New York
Fellowship: Medical Oncology, Roswell Cancer Institute, University of Buffalo, Buffalo, New York
|Board Certification and Licensure
Medical License: Texas
|Clinical and Research Interests
1: Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, Dipersio JF, Catalano JV,
Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO,
Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W,
Sandor V, Kantarjian HM. The clinical benefit of ruxolitinib across patient
subgroups: analysis of a placebo-controlled, Phase III study in patients with
myelofibrosis. Br J Haematol. 2013 May;161(4):508-16. doi: 10.1111/bjh.12274.
Epub 2013 Mar 11. PubMed PMID: 23480528.
2: Fiskus W, Verstovsek S, Manshouri T, Smith JE, Peth K, Abhyankar S, McGuirk J,
Bhalla KN. Dual PI3K/AKT/mTOR Inhibitor BEZ235 Synergistically Enhances the
Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative
Neoplasm Cells. Mol Cancer Ther. 2013 Apr 26. [Epub ahead of print] PubMed PMID:
3: Jain P, Kantarjian H, Nazha A, O'Brien S, Jabbour E, Guillermo Romo C, Pierce
S, Cardenas-Turanzas M, Verstovsek S, Borthakur G, Ravandi F, Quintás-Cardama A,
Cortes J. Early responses predicts for better outcomes in patients with newly
diagnosed CML: results with four TKI modalities. Blood. 2013 Apr 25. [Epub ahead
of print] PubMed PMID: 23620574.
4: Santos FP, Tam CS, Kantarjian H, Cortes J, Thomas D, Pollock R, Verstovsek S.
Splenectomy in patients with Myeloproliferative Neoplasms: efficacy,
complications and impact on survival and transformation. Leuk Lymphoma. 2013 Apr
11. [Epub ahead of print] PubMed PMID: 23573823.